Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01589952

Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB) (Bangabandhu)

Pilot Study of First Line Combination Treatment With Low Dose Pegylated Interferon and Entecavir in Treatment-naïve Patients With Chronic Hepatitis B.

Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Conditions Chronic Hepatitis B

Interventions Pegalyted interferon, Entecavir

Updated 4 times since 2017 Last updated: May 1, 2012 Started: Mar 31, 2012 Primary completion: Feb 28, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Chronic Hepatitis B and is currently ongoing. Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh leads this study, which shows 4 recorded versions since 2012 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Data source: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dhaka, Bangladesh